HuidaGene Therapeutics Gains FDA Clearance for First CRISPR/Cas13 RNA-Editing Therapy HG202 to Treat Macular Degeneration

Complete Genomics Unveils New Sequencing Innovations and Expanded DNBSEQ-T7 Applications at ASHG 2024

QIAGEN’s QIAstat-Dx Meningitis/Encephalitis Panel Gains FDA Clearance, Accelerating CNS Infection Diagnosis

Tempus AI to Acquire Ambry Genetics for $600 Million, Expanding Genetic Testing Capabilities

Aiforia and Paige form strategic partnership to advance AI integration in pathology laboratories

CytoDyn Receives FDA Clearance to Begin Phase II Trial of Leronlimab for Colorectal Cancer

MGM Medical College in Indore Pioneers CAR T Cell Therapy for Blood Cancer Treatment in India’s Public Healthcare System

AbbVie and EvolveImmune Therapeutics Partner in New Collaboration and Licensing Agreement to Advance Next-Generation Cancer Biotherapeutics

Cardiff Oncology Publishes Phase 2 Trial Data on Second-Line Treatment for KRAS-Mutant mCRC in *Journal of Clinical Oncology*

Advanced Genomics APAC and Compass Bioinformatics Forge Strategic Alliance to Enhance Rare Disease and Cancer Diagnostics in APAC Region

Telo Genomics Expands Mayo Clinic Collaboration to Advance Multiple Myeloma Prognostic Testing

Daiichi Sankyo and AstraZeneca Launch Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations in Advanced Non-Small Cell Lung Cancer

FDA Approves Novartis Scemblix® for Newly Diagnosed CML, Showcasing Superior Efficacy and Improved Safety Profile

IDEAYA Biosciences Secures IND Clearance for IDE275 (GSK959) to Initiate Phase 1 Trial in MSI-High Solid Tumors

MGI Partners with OncoDNA to Enhance Precision Oncology with Compatible Genomic Solutions

Home
/
update
/
details

QIAGEN’s QIAstat-Dx Meningitis/Encephalitis Panel Gains FDA Clearance, Accelerating CNS Infection Diagnosis

NextEdge Admin

05 Nov 2024

2 min 9 sec

QIAGEN has announced FDA clearance of its QIAstat-Dx Meningitis/Encephalitis Panel, marking the fourth syndromic panel approval for QIAstat-Dx in 2024. Designed for rapid diagnosis of central nervous system infections, this panel aids clinicians by providing results within about one hour using real-time PCR technology. Traditional microbiological testing can take up to 24 hours and may lack sensitivity, a challenge for meningitis and encephalitis cases where quick action is crucial to prevent severe outcomes, including brain damage and seizures.

The QIAstat-Dx system enhances testing efficiency by analyzing multiple genetic targets simultaneously to detect common viral, bacterial, and fungal pathogens that cause community-acquired meningitis and encephalitis. Unique to QIAstat-Dx, the system provides cycle threshold (Ct) values and amplification curves, offering detailed insights into detected pathogens beyond typical PCR capabilities.

With this new panel, QIAGEN now offers a suite of FDA-cleared tests addressing respiratory, gastrointestinal, and central nervous system infections. Other recent approvals include the QIAstat-Dx Gastrointestinal Panel 2, Respiratory Panel Plus, and Respiratory Panel Mini. Each QIAstat-Dx test utilizes single-use, preloaded cartridges that simplify setup, requiring less than a minute without precision pipetting. This design, coupled with software that automatically interprets results, supports fast, evidence-based clinical decision-making. QIAGEN's ongoing expansion of its U.S. test menu underscores its commitment to advancing diagnostics for timely and accurate patient care.